1 Gilden, D. H., Mahalingam, R., Cohrs, R. J. & Tyler, K. L. Herpesvirus infections of the nervous system. Nat. Clin. Pract. Neurol. 3, 82–94 (2007).

2 Owen, C. B. et al. Utilising proteomic approaches to understand oncogenic human herpesviruses (Review). Mol. Clin. Oncol. 2, 891–903 (2014).

3 Quadrelli, C. et al. β-HHVs and HHV-8 in lymphoproliferative disorders. Mediterr. J. Hematol. Infect. Dis. 3, e2011043 (2011).

4 Ganem, D. KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu. Rev. Pathol. 1, 273–296 (2006).

5 Mesri, E. A., Cesarman, E. & Boshoff, C. Kaposi's sarcoma and its associated herpesvirus. Nat. Rev. Cancer 10, 707–719 (2010).

6 Arvanitakis, L., Geras-Raaka, E., Varma, A., Gershengorn, M. C. & Cesarman, E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 385, 347–350 (1997).

7 Vart, R. J. et al. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res. 67, 4042–4051 (2007).

8 Nicholas, J. et al. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat. Med. 3, 287–292 (1997).

9 Tomlinson, C. C. & Damania, B. The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway. J. Virol. 78, 1918–1927 (2004).

10 Brinkmann, M. M. et al. Activation of mitogen-activated protein kinase and NF-κB pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein. J. Virol. 77, 9346–9358 (2003).

11 Jackson, B. R., Noerenberg, M. & Whitehouse, A. A novel mechanism inducing genome instability in Kaposi's sarcoma-associated herpesvirus infected cells. PLoS Pathogens 10, e1004098 (2014).

12 Bacon, T. H., Levin, M. J., Leary, J. J., Sarisky, R. T. & Sutton, D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin. Microbiol. Rev. 16, 114–128 (2003).

13 Fife, K. et al. Cidofovir for the treatment of Kaposi's sarcoma in an HIV-negative homosexual man. Br. J. Dermatol. 141, 1136–1152 (1999).

14 Mazzi, R. et al. Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS. AIDS 15, 2061–2062 (2001).

15 Little, R. F. et al. A pilot study of cidofovir in patients with Kaposi sarcoma. J. Infect. Dis. 187, 149–153 (2003).

16 Martin, D. F. et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N. Engl. J. Med. 340, 1063–1070 (1999).

17 Glesby, M. J. et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the multicenter AIDS cohort study. J. Infect. Dis. 173, 1477–1480 (1996).

18 Cordin, O., Banroques, J., Tanner, N. K. & Linder, P. The DEAD-box protein family of RNA helicases. Gene 367, 17–37 (2006).

19 Shadrick, W. R. et al. Discovering new medicines targeting helicases: challenges and recent progress. J. Biomol. Screen. 18, 761–781 (2013).

20 Chen, C.-S. et al. Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase. J. Med. Chem. 52, 2716–2723 (2009).

21 Artsaenko, O., Tessmann, K., Sack, M., Häussinger, D. & Heintges, T. Abrogation of hepatitis C virus NS3 helicase enzymatic activity by recombinant human antibodies. J. Gen. Virol. 84, 2323–2332 (2003).

22 Hwang, B. et al. Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus. RNA 10, 1277–1290 (2004).

23 Lindqvist, L. et al. Selective pharmacological targeting of a DEAD Box RNA helicase. PLoS ONE 3, e1583 (2008).

24 Tsumuraya, T. et al. Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem. Pharmacol. 81, 713–722 (2011).

25 Yedavalli, V. S. R. K. et al. Ring expanded nucleoside analogues inhibit RNA helicase and intracellular human immunodeficiency virus type 1 replication. J. Med. Chem. 51, 5043–5051 (2008).

26 Boyne, J. R. & Whitehouse, A. γ-2 Herpes virus post-transcriptional gene regulation. Clin. Microbiol. Infect. 12, 110–117 (2006).

27 Schumann, S., Jackson, B., Baquero-Perez, B. & Whitehouse, A. Kaposi's sarcoma-associated herpesvirus ORF57 protein: exploiting all stages of viral mRNA processing. Viruses 5, 1901–1923 (2013).

28 Boyne, J. R., Jackson, B. R., Taylor, A., Macnab, S. A. & Whitehouse, A. Kaposi's sarcoma-associated herpesvirus ORF57 protein interacts with PYM to enhance translation of viral intronless mRNAs. EMBO J. 29, 1851–1864 (2010).

29 Jackson, B. R. et al. An interaction between KSHV ORF57 and UIF provides mRNA-adaptor redundancy in herpesvirus intronless mRNA export. PLoS Pathogens 7, e1002138 (2011).

30 Hautbergue, G. M. et al. UIF, a new mRNA export adaptor that works together with REF/ALY, requires FACT for recruitment to mRNA. Curr. Biol. 19, 1918–1924 (2009).

31 Dufu, K. et al. ATP is required for interactions between UAP56 and two conserved mRNA export proteins, Aly and CIP29, to assemble the TREX complex. Genes Dev. 24, 2043–2053 (2010).

32 Chang, C. T. et al. Chtop is a component of the dynamic TREX mRNA export complex. EMBO J. 32, 473–486 (2013).

33 Boyne, J. R., Colgan, K. J. & Whitehouse, A. Recruitment of the complete hTREX complex is required for Kaposi's sarcoma-associated herpesvirus intronless mRNA nuclear export and virus replication. PLoS Pathogens 4, e1000194 (2008).

34 Shi, H., Cordin, O., Minder, C. M., Linder, P. & Xu, R.-M. Crystal structure of the human ATP-dependent splicing and export factor UAP56. Proc. Natl Acad. Sci. USA 101, 17628–17633 (2004).

35 Dymock, B. W. et al. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J. Med. Chem. 48, 4212–4215 (2005).

36 Shen, J., Zhang, L. & Zhao, R. Biochemical characterization of the ATPase and helicase activity of UAP56, an essential pre-mRNA splicing and mRNA export factor. J. Biol. Chem. 282, 22544–22550 (2007).

37 Sharp, S. Y. et al. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res. 67, 2206–2216 (2007).

38 Boyne, J. R. & Whitehouse, A. Nucleolar disruption impairs Kaposi's sarcoma-associated herpesvirus ORF57-mediated nuclear export of intronless viral mRNAs. FEBS Lett. 583, 3549–3556 (2009).

39 Schumann, S., Baquero-Perez, B. & Whitehouse, A. Interactions between KSHV ORF57 and the novel human TREX proteins, CHTOP and CIP29. J. Gen. Virol. 97, 1904–1910 (2016).

40 Stubbs, S. H., Hunter, O. V., Hoover, A. & Conrad, N. K. Viral factors reveal a role for REF/Aly in nuclear RNA stability. Mol. Cell. Biol. 32, 1260–1270 (2012).

41 Nakamura, H. et al. Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. J. Virol. 77, 4205–4220 (2003).

42 Chen, W., Sin, S.-H., Wen, K. W., Damania, B. & Dittmer, D. P. Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathogens 8, e1003048 (2012).

43 Nayar, U. et al. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood 122, 2837–2847 (2013).

44 Higashi, C. et al. The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells. Biol. Pharm. Bull. 35, 725–730 (2012).

45 Zhao, R., Shen, J., Green, M. R., MacMorris, M. & Blumenthal, T. Crystal structure of UAP56, a DExD/H-box protein involved in pre-mRNA splicing and mRNA export. Structure 12, 1373–1381 (2004).

46 Nielsen, K. H. et al. Mechanism of ATP turnover inhibition in the EJC. RNA 15, 67–75 (2009).

47 Smith, N. F. et al. Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors. Mol. Cancer Ther. 5, 1628–1637 (2006).

48 Tunnicliffe, R. B. et al. Structural basis for the recognition of cellular mRNA export factor REF by herpes viral proteins HSV-1 ICP27 and HVS ORF57. PLoS Pathogens 7, e1001244 (2011).

49 Lischka, P., Toth, Z., Thomas, M., Mueller, R. & Stamminger, T. The UL69 transactivator protein of human cytomegalovirus interacts with DEXD/H-box RNA helicase UAP56 to promote cytoplasmic accumulation of unspliced RNA. Mol. Cell. Biol. 26, 1631–1643 (2006).

50 Read, E. K. C. & Digard, P. Individual influenza A virus mRNAs show differential dependence on cellular NXF1/TAP for their nuclear export. J. Gen. Virol. 91, 1290–1301 (2010).

51 Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S. & Coleman, R. G. ZINC: a free tool to discover chemistry for biology. J. Chem. Inf. Model. 52, 1757–1768 (2012).

52 Cheng, H. et al. Human mRNA export machinery recruited to the 5’ end of mRNA. Cell 127, 1389–1400 (2006).

53 Hughes, D. J., Wood, J. J., Jackson, B. R., Baquero-Pérez, B. & Whitehouse, A. NEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target. PLoS Pathogens 11, e1004771 (2015).

54 Griffiths, D. A. et al. Merkel cell polyomavirus small T antigen targets the NEMO adaptor protein to disrupt inflammatory signaling. J. Virol. 87, 13853–13867 (2013).